A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs SynKIR 110 (Primary) ; SynKIR 310 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Acronyms LTFU study
- Sponsors Verismo Therapeutics
- 28 Nov 2024 New trial record